Adlon Therapeutics L.P. Sustainability Profile
Adlon Therapeutics L.P., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2015, the company has rapidly established itself as a leader in developing innovative therapies for central nervous system disorders. Adlon Therapeutics focuses on creating unique solutions that address unmet medical needs, particularly in the realm of attention-deficit/hyperactivity disorder (ADHD). With a commitment to advancing patient care, Adlon's core products are distinguished by their novel formulations and delivery mechanisms, which enhance efficacy and patient compliance. The company has achieved significant milestones, including successful clinical trials that underscore its market position. As a result, Adlon Therapeutics continues to make strides in the biopharmaceutical landscape, contributing to the improvement of lives through its cutting-edge therapeutic offerings.
DitchCarbon Score
How does Adlon Therapeutics L.P.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adlon Therapeutics L.P.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adlon Therapeutics L.P.'s reported carbon emissions
Adlon Therapeutics L.P., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Adlon Therapeutics L.P. may inherit climate-related data and commitments from its parent organisation; however, no specific details regarding such cascaded data have been provided. This lack of emissions reporting and reduction initiatives suggests that Adlon Therapeutics L.P. is still in the early stages of developing its climate strategy or may rely on broader corporate family commitments for guidance. In the context of the pharmaceutical industry, companies are increasingly expected to establish clear climate commitments and reduction targets to align with global sustainability goals. Adlon Therapeutics L.P. will need to consider these industry standards as it develops its approach to carbon emissions and climate action.
How Carbon Intensive is Adlon Therapeutics L.P.'s Industry?
How Carbon Intensive is Adlon Therapeutics L.P.'s Location?
Adlon Therapeutics L.P.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adlon Therapeutics L.P. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
